BMND07

Last updated
BMND07
Combination of
Dimethyltryptamine Serotonin receptor agonist Serotonergic psychedelic; Hallucinogen
5-MeO-DMT Serotonin receptor agonist Serotonergic psychedelic; Hallucinogen
Clinical data
Other namesBMND-07

BMND07, or BMND-07, is a combination of either dimethyltryptamine (DMT) or 5-MeO-DMT and another undisclosed compound which is under development for the treatment of depressive disorders. [1] [2] [3] [4] It is being developed by Biomind Labs. [1] [2] As of March 2022, it is in phase 1 clinical trials. [1] [2]

Contents

See also

References

  1. 1 2 3 "BMND 07". AdisInsight. 16 March 2022. Retrieved 16 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on BMND-07 with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. ↑ "Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND07". BioSpace. 3 March 2022. Retrieved 16 February 2025. Biomind Labs' BMND07 drug candidate, a novel DMT combination drug, [...]
  4. ↑ "Biomind Labs Provides Corporate Update". Business Wire. 27 September 2023. Retrieved 16 February 2025. BMND07: 5-methoxy-DMT ("5-MeO-DMT") free base organic synthesis



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.